Efti Development Program For Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Efti Development Program For Cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Efti Development Program For Cancer Today - Breaking & Trending Today

Immutep quarterly activities report & Appendix 4C

Published: October 25, 2022

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today provides an update on the ongoing development of its product candidates, eftilagimod alpha ("efti") and IMP761 for the quarter ended ...

Source: pharmiweb.com

Related Topics:

United StatesNew South WalesImmutep LimitedSociety For Immunotherapy Of CancerCurie National Research Institute Of OncologyDrug AdministrationRussian Patent OfficeEfti Development Program For CancerDevelopment Program For Autoimmune DiseaseResearch An DevelopmentInstitute Of Clinical Cancer ResearchCurie National Research InstituteJapanese Patent OfficeDevelopment ProgramLung CancerOverall SurvivalUnited States FoodFast TrackAnnual MeetingClinical Cancer ResearchNorthwest HospitalSoft TissueJapanese PatentChief Scientific OfficerChief Medical Officer